Journal
BLOOD
Volume 129, Issue 17, Pages 2408-2419Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2016-08-731166
Keywords
-
Categories
Funding
- Ministerio de Economia y Competitividad's research training program (Formacion de Personal Investigador [FPI]) fellowship
- Ramon y Cajal program - Ministerio de Educacion, Cultura y Deporte [RYC-2009-04503]
- European Research Council Proof of Concept program [HEAL-BY-MIRNA 713728]
- Centro Nacional de Investigaciones Cardiovaculares (CNIC)
- Ministerio de Economia y Competitividad [SAF2010-21394, SAF2013-42767-R, BIO2012-37926, BIO2015-67580-P]
- European Research Council [BCLYM-207844]
- Proof of Concept program [HEAL-BY-MIRNA 713728]
- People Programme-Marie Curie Actions [FP7-PIIF-2012-328177]
- Spanish Ministry of Economy and Competitiveness (MINECO) [SAF2013-45787-R]
- Gobierno de Navarra [GN-106/2014]
- Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria [FIS] [PRB2 [IPT13/0001]]
- Fundacion La Marato TV3
- Redes tematicas de investigacion cooperativa en salud [RETICS] [RD12/0042/00056]
- Fondo Europeo de Desarrollo Regional (FEDER) funds
- Pro CNIC Foundation
- Severo Ochoa Center of Excellence (MINECO) [SEV-2015-0505]
Ask authors/readers for more resources
Non-Hodgkin lymphoma comprises a variety of neoplasms, many of which arise from germinal center (GC)-experienced B cells. microRNA-28 (miR-28) is a GC-specific miRNA whose expression is lost in numerous mature B-cell neoplasms. Here we show that miR-28 regulates the GC reaction in primary B cells by impairing class switch recombination and memory B and plasma cell differentiation. Deep quantitative proteomics combined with transcriptome analysis identified miR-28 targets involved in cell-cycle and B-cell receptor signaling. Accordingly, we found that miR-28 expression diminished proliferation in primary and lymphoma cells in vitro. Importantly, miR-28 reexpression in human Burkitt (BL) and diffuse large B-cell lymphoma (DLBCL) xenografts blocked tumor growth, both when delivered in viral vectors or as synthetic, clinically amenable, molecules. Further, the antitumoral effect of miR-28 is conserved in a primary murine in vivo model of BL. Thus, miR-28 replacement is uncovered as a novel therapeutic strategy for DLBCL and BL treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available